Concurrent immune-mediated hemolytic anemia and severe thrombocytopenia in 21 dogs

Department of Veterinary Clinical Sciences, Royal Veterinary College, Hawkshead Lane, North Mymms, Hertfordshire.
The Veterinary record (Impact Factor: 1.49). 10/2008; 163(11):323-7. DOI: 10.1136/vr.163.11.323
Source: PubMed


The medical records of 21 dogs with concurrent immune-mediated haemolytic anaemia (imha) and severe thrombocytopenia (defined as an automated platelet count of less than 50x10(9)/l, confirmed by the examination of a blood smear) were reviewed. Their mean (sd) age was 5.8 (2.5) years. When compared with the 24,759 dogs in the hospital population for the same period Airedale terriers and dobermanns appeared to be over-represented with odds ratios of 22.5 (95 per cent confidence interval [ci] 5.2 to 97.9) and 7.6 (95 per cent ci 1.8 to 32.7) respectively. The median duration of the dogs' clinical signs was seven days, with a range from one to 17 days. Eleven of the dogs had a history of a tendency to bleed, and 15 had evidence of bleeding when examined. Twenty of the 21 dogs had been treated with glucocorticoids, nine with vincristine, and seven with azathioprine. Their median stay in hospital was four days, with a range from one to 17 days. The median period for which they survived after admission to hospital was five days, with a range from one to 558 days, and 16 of the 21 dogs had died or been euthanased within 30 days of their admission.

Download full-text


Available from: Daniel L Chan, Jan 31, 2016
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immune-mediated thrombocytopenia (IMT) is a common hematologic disorder in dogs. Human intravenous immunoglobulin (hIVIG) may have a beneficial effect in canine IMT. A single hIVIG infusion (0.5 g/kg) in dogs with presumed primary IMT (pIMT) is a safe adjunctive emergency treatment to accelerate platelet count recovery and shorten hospitalization time without increasing the cost of patient care. Eighteen client-owned dogs with a presumptive diagnosis of pIMT. Prospective, randomized, double-blinded, placebo-controlled clinical trial. There were no identifiable immediate or delayed adverse reactions associated with hIVIG administration over a 6-month period. The median platelet count recovery time for the hIVIG group was 3.5 days (mean + or - SD: 3.7 + or - 1.3 days; range, 2-7 days) and 7.5 days (mean + or - SD: 7.8 + or - 3.9 days; range, 3-12 days) for the placebo group. The median duration of hospitalization for hIVIG group was 4 days (mean + or - SD: 4.2 + or - 0.4 days; range, 2-8 days) and 8 days (mean + or - SD: 8.3 + or - 0.6 days; range, 4-12 days) for the placebo group. There was no significant difference between groups with respect to expense of initial patient care, whereas significant reduction in platelet count recovery time (P= .018) and duration of hospitalization (P= .027) were detected in the hIVIG group. Compared with corticosteroids alone, adjunctive emergency therapy of a single hIVIG infusion was safe and associated with a significant reduction in platelet count recovery time and duration of hospitalization without increasing the expense of medical care in a small group of dogs with presumed pIMT.
    No preview · Article · Sep 2009 · Journal of Veterinary Internal Medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunomodulators, immunostimulants, and immunotherapies are important tools used by veterinary practitioners and researchers to control and direct the immune system of small animals. This article is an overview and summary of some of the most common immunomodulatory agents used in companion animals emphasizing steroidal and nonsteroidal agents, T-cell inhibitors, cytotoxic drugs, immunostimulators and biologic response modifying agents, and neoplasia chemotherapeutic agents.
    No preview · Article · May 2010 · Veterinary Clinics of North America Small Animal Practice
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are many autoimmune diseases recognized in humans; many of these have counterparts in companion animals. The diseases discussed in this article do not constitute the entire spectrum of autoimmune disease in these species. They are the common and better-described diseases of dogs and cats that have a well-documented autoimmune etiology. There are myriad autoimmune diseases that affect humans; similar diseases yet unrecognized in companion animals likely will be characterized in the future. The role of genetics in predisposition to autoimmunity is a common characteristic of these diseases in humans and animals. Likewise, the suggested role of environmental or infectious agents is another commonality between humans and their pets.
    No preview · Article · May 2010 · Veterinary Clinics of North America Small Animal Practice
Show more